Our seasoned team of scientists have dedicated their lives’ work to the discovery and development of sight-preserving treatments. In some cases, this means spotlighting new applications for established therapies. In other areas, we’re developing new molecules and medicines to potentially change the standard of care for preventable blindness.
We’ve got a laser focus on the future and it shows in our pipeline.
LEARN ABOUT OUR LEAD CANDIDATE BRIMOCHOLTM PFVisus Therapeutics is dedicated to helping the billions of adults who suffer from presbyopia through the development of its investigational medicine, BRIMOCHOL™. BRIMOCHOL is being studied as a prescription eye drop designed to correct the loss of near vision associated with presbyopia.
Presbyopia is the gradual loss of near vision that affects 128 million US adults.1,2 Part of the normal aging process, presbyopia usually begins to appear in adults in their 40s and 50s3 and requires reading glasses or bifocals to correct.
BRIMOCHOL PF is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). Together, they produce a “pinhole effect,” which reduces the size of the pupil so that only centrally focused light rays are able to enter the eye, thereby sharpening distant and near images while minimizing side effects.
Learn more about BRIMOCHOLTM PF
Corneal injury from a variety of acute or chronic conditions can result in patients’ dissatisfaction with visual performance or surgical outcomes. Delayed or poor corneal healing from post-PRK surgery, infections, corneal ulcer, acute dry eye, and post-collagen cross-linking for keratoconus, and neurotropic keratitis are but a few acute conditions. Chronic conditions can include keratoconus, Fuch’s corneal dystrophy, contact lens intolerance, and chronic dry eye. Increasing the speed of recovery from acute or resolution of chronic corneal injury may translate into improved vision outcomes and increased patients’ satisfaction.
VT-1020 is related to a family of salivary and lacrimal peptides known as histatins that have potent wound healing, antimicrobial, and anti-inflammatory properties. In animal and in vitro studies, histatins have been shown to enhance corneal epithelial migration and spreading, increase the rate of wound closure from surgical procedures through rapid re-epithelization, and inhibit pro-inflammatory cytokines Il-6, IL-8,TNF-α, MMP-2, and MMP-9. These factors may mitigate corneal injury in both acute and chronic conditions.
Intraocular pressure (IOP) is the measurement of the pressure inside of the eye. In a healthy eye, a small amount of aqueous humor constantly enters the eye while an equal amount drains out of the eye. This equal flow creates a stable intraocular pressure. When this drainage mechanism does not work properly, the fluid can build up, raising the pressure inside the eye, leading to a condition called ocular hypertension. If the increase in pressure is severe or prolonged, irreversible damage can occur to the retina and optic nerve, leading to a loss in vision in some patients, a condition called glaucoma.
VT-1031 is a novel, injectable, sustained-release delivery system that delivers an active pharmaceutical ingredient for lowering IOP directly to the vitreous. The system is designed to provide sustained IOP lowering and bioerode as the drug is released. By delivering directly to the vitreous, it is expected that the potential for physical damage to the corneal endothelial cells observed with some intracameral systems will be greatly reduced. Initial animal studies have demonstrated a prostaglandin-like pressure reduction after intravitreal administration of VT-1031. This technology has the potential to greatly improve patient compliance with medication regimens, reduce pressure fluctuations, and improve outcomes in patients with ocular hypertension or glaucoma.
Glaucoma is a group of diseases that cause damage to the optic nerve and can result in vision loss and blindness. It is estimated that about 3 million adults in the US have glaucoma, and it is the second leading cause of blindness globally.1
Glaucoma is often caused by high intraocular pressure (IOP), leading to retinal and optic nerve damage. While lowering IOP is currently the only effective treatment for glaucoma, targeting other pathways of retinal and optic nerve injury may offer additional benefits.
VT-1041 is a novel, injectable, sustained-release delivery system that delivers an IOP-lowering agent and a CNTF analog. With the addition of the CNTF analog, VT-1041 has the potential to control intraocular pressures, prevent further vision loss, and improve vision in some glaucoma patients.
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD), affecting the retina, the light-sensitive tissue at the back of the eye that sends information to the brain to enable sight.1
AMD is a leading cause of vision loss for older adults.2 AMD does not cause complete blindness, but affects central vision, making it harder to see faces, read, drive, or do other closer-up tasks.
VT-1051 is a novel, injectable, sustained-release delivery system that delivers a CNTF analog and a FAS/TNF-α inhibitor that has the potential to preserve photoreceptors, prevent programmed cell death, and improve vision in GA.
© VISUS THERAPEUTICS 2021 ALL RIGHTS RESERVED
VISUS THERAPEUTICS and BRIMOCHOL are trademarks of Visus Therapeutics, Inc.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
